Penicillin-G acylases
US-10781436-B2 · Sep 22, 2020 · US
Penicillin-G acylases
US12378541B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12378541-B2 |
| Application number | US-202117504852-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 19, 2021 |
| Priority date | May 7, 2015 |
| Publication date | Aug 5, 2025 |
| Grant date | Aug 5, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to engineered penicillin G acylase (PGA) enzymes having improved properties, polynucleotides encoding such enzymes, compositions including the enzymes, and methods of using the enzymes.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for producing free insulin, comprising: i) providing an engineered penicillin G acylase capable of removing A1/B1/B29 tri-phenyl acetate protecting groups from insulin to produce free insulin, wherein said penicillin G acylase is at least 95% identical to SEQ ID NO: 6, and wherein said engineered penicillin G acylase comprises an alanine at position 264, an asparagine at position 484, and a lysine at position 547, wherein said positions are numbered with reference to SEQ ID NO: 6 and insulin comprising A1/B1/B29 tri-phenyl acetate protecting groups; and ii) exposing said engineered penicillin G acylase to said insulin comprising A1/B1/B29 tri-phenyl acetate protecting groups under conditions such that said engineered penicillin G acylase removes the A1/B1/B29 tri-phenyl acetate protecting groups and free insulin is produced. 2. The method of claim 1 , wherein said engineered penicillin G acylase removes the A1/B1/B29 tri-phenyl acetate protecting groups from more than 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% of the insulin comprising A1/B1/B29 tri-phenyl acetate protecting groups to produce free insulin. 3. The method of claim 1 , wherein said penicillin G acylase comprises SEQ ID NO: 6, 10, or 12.
Assignees
Inventors
Classifications
Penicillin amidase (3.5.1.11), i.e. penicillin-amidohydrolase · CPC title
Preparation of peptides or proteins (single cell protein C12N1/00) · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
for increasing or potentiating the activity of insulin · CPC title
- C12N9/84Primary
Penicillin amidase {(3.5.1.11)} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12378541B2 cover?
- The present disclosure relates to engineered penicillin G acylase (PGA) enzymes having improved properties, polynucleotides encoding such enzymes, compositions including the enzymes, and methods of using the enzymes.
- Who is the assignee on this patent?
- Codexis Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N9/84. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).